<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D4FF7C8F-C29F-420F-A626-2348EA059004"><gtr:id>D4FF7C8F-C29F-420F-A626-2348EA059004</gtr:id><gtr:name>Novacta Biosystems Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/BD1136E3-4221-4BC4-B7E3-2C031077449F"><gtr:id>BD1136E3-4221-4BC4-B7E3-2C031077449F</gtr:id><gtr:name>Prolysis Ltd</gtr:name><gtr:address><gtr:line1>Prolysis Ltd</gtr:line1><gtr:line2>Begbroke Science Park</gtr:line2><gtr:line3>Sandy Lane</gtr:line3><gtr:line4>Yarnton</gtr:line4><gtr:line5>Oxfordshire</gtr:line5><gtr:postCode>OX5 1PF</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5D55E165-233B-426B-B629-5FFC887C1004"><gtr:id>5D55E165-233B-426B-B629-5FFC887C1004</gtr:id><gtr:name>MRC Technology (MRCT)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:department>Biological Sciences</gtr:department><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D4FF7C8F-C29F-420F-A626-2348EA059004"><gtr:id>D4FF7C8F-C29F-420F-A626-2348EA059004</gtr:id><gtr:name>Novacta Biosystems Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/BD1136E3-4221-4BC4-B7E3-2C031077449F"><gtr:id>BD1136E3-4221-4BC4-B7E3-2C031077449F</gtr:id><gtr:name>Prolysis Ltd</gtr:name><gtr:address><gtr:line1>Prolysis Ltd</gtr:line1><gtr:line2>Begbroke Science Park</gtr:line2><gtr:line3>Sandy Lane</gtr:line3><gtr:line4>Yarnton</gtr:line4><gtr:line5>Oxfordshire</gtr:line5><gtr:postCode>OX5 1PF</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5D55E165-233B-426B-B629-5FFC887C1004"><gtr:id>5D55E165-233B-426B-B629-5FFC887C1004</gtr:id><gtr:name>MRC Technology (MRCT)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/DC3E968D-06C2-4F03-9987-D58301F99BC6"><gtr:id>DC3E968D-06C2-4F03-9987-D58301F99BC6</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:otherNames>Gerrard</gtr:otherNames><gtr:surname>Dowson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/81141413-9AE6-4662-BD73-F91C42871C65"><gtr:id>81141413-9AE6-4662-BD73-F91C42871C65</gtr:id><gtr:firstName>Adrian</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Lloyd</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/1FD4D789-FFE2-40DF-91BF-73143F6A553A"><gtr:id>1FD4D789-FFE2-40DF-91BF-73143F6A553A</gtr:id><gtr:firstName>David Ian</gtr:firstName><gtr:surname>Roper</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/DDBB3F10-D3B5-4C13-BD8E-415EF8EBE9C9"><gtr:id>DDBB3F10-D3B5-4C13-BD8E-415EF8EBE9C9</gtr:id><gtr:firstName>Timothy</gtr:firstName><gtr:otherNames>David Howard</gtr:otherNames><gtr:surname>Bugg</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0400848"><gtr:id>2802C6EC-BD85-4102-A6F2-2BBC776FA7FD</gtr:id><gtr:title>Exploration and exploitation of the enzymology of PBP driven peptidoglycan</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400848</gtr:grantReference><gtr:abstractText>Millions of people die each year from bacterial infections and tens of millions suffer from non-fatal disease. The discovery of penicillin opened the door to treat these infections with antibiotics. Penicillin is one of the most important antibiotics in the world and works by stopping bacteria making the polymer in the cell wall that holds them together. This polymer, calle dpeptidoglycan, is made up of an interlocking network of sugars and strings of amino acids (peptides). Specialised proteins (called PBPs), with the ability to stitch together these sugars and peptides are the targets inhibited by penicillin, stopping cell wall synthesis and killing the bacterium. However, after all this time no one really knows how these PBPs work in making cell wall. 

It is now more important then ever that we understand this mechanism. Many important bacteria are now no longer killed by penicillin - they have altered their PBPs so that they can still make cell wall but prevent penicillin from inhibiting these proteins. The group at Warwick has brought together a team from microbiology, biochemistry, chemistry and structural biology to crack this problem. They have, for the first time, the combined tools and new chemical reagents (made at Warwick) to look in minute detail how PBPs work and how antibiotic resistance has developed at the molecular level within these proteins.

This ability at Warwick has interested Pharmaceutical companies looking to design new antibiotics to kill bacteria that are resistant to penicillin. Prolysis, perhaps the premier bacterial drug discovery company within the UK and Europe, has linked up with the team at Warwick as collaborators to make their extensive company computing resources, robotics, and chemical library, available for use with this new ability in the quest for novel life saving antibiotics.</gtr:abstractText><gtr:technicalSummary>The terminal stages of bacterial cell wall (peptidoglycan) biosynthesis is driven by a family of specialised transpeptidases better known as penicillin-binding proteins or PBPs (some of which also possess additional transglycosylase domains). These enzymes are important, being the targets for penicillin and other b-lactam antibiotics. However, PBPs have evolved genetic variants with low affinities for these antibiotics, rendering them therapeutically ineffective. For Streptococcus pneumoniae homologous recombinaitons to PBPs 1A, 2X and 2B has resulted in changes to amino acid composition and transpeptidase conformation. Furthermore, the cell wall composition of highly resistant strains indicates that these PBPs have to process modified substrate.
Important as they are, almost nothing is understood about how these proteins interact with their natural substrate, lipid II, a disaccharide conjugated to a pentapeptide and linked to a C55 undecaprenyl lipid carrier, during cell wall assembly (PBPs cross linking the disaccharide and peptide components of lipid II). The previous inability to easily synthesise this substrate has substantially hindered progress.
At Warwick we have recently developed and validated a continuous PBP assay based upon the natural substrate. We are able to synthesise; lipid II (and its MurMN mediated (Ser Ala ) peptide variants found in highly resistant strains) in quantity at high purity ( 98%); lipid I and its MurNAC peptide precursors; soluble S. pneumoniae PBPs, 1A (with transglycosylase and transpeptidase activity) , and 2X and 2B (with transpeptidase activity) from susceptible and resistant strains; site directed PBP mutants; and the reagents to establish a high throughput continuous kinetic analysis of these PBPs.
This long awaited breakthrough will enable a thorough kinetic and mechanistic analysis of amino acid alterations identified as being important in resistance. We will also be able to investigate; the impact PBP and stem peptide alterations have upon the kinetics of high and low affinity PBPs; and the interplay of transglycosylase and transpeptidase activity in substrate utilisation.
In addition to examining at the molecular level the evolution of penicillin resistance in S. pneumoniae, we, with our drug discovery collaborators, Prolysis, will use our PBP assay to establish a high throughput screen to identify novel non-b-lactam PBP inhibitors. 
The natural substrate will also enable us to undertake co-crystallisation studies of enzymes and substrate, to better determine the binding and mechanism of action of these enzymes, and so help in the rational identification of novel inhibitors as part of the drug discovery programme.</gtr:technicalSummary><gtr:fund><gtr:end>2008-05-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>341175</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novacta Biosystems Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Novacta</gtr:description><gtr:id>189EC756-822D-4912-8F4C-FA1624FB78B4</gtr:id><gtr:impact>Novacta became industrial advisors as part of our MRC programme grant application and Mike Dawson from Novacta still performs this function</gtr:impact><gtr:partnerContribution>Indistrial focussed advice</gtr:partnerContribution><gtr:piContribution>updating company on our assay development and screening capabilities</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MRC Technology (MRCT)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRCT Centre for Therapeutics Discovery (CTD)</gtr:department><gtr:description>MRCT</gtr:description><gtr:id>7BB10EF9-148A-42F5-ACF0-ED059AC3E7E4</gtr:id><gtr:impact>DPFS grant applications</gtr:impact><gtr:partnerContribution>Pump priming drug discovery research and further grant applications to MRC</gtr:partnerContribution><gtr:piContribution>Provision of reagents and assays, developing structural information</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Vicuron Pharmaceuticals</gtr:department><gtr:description>Ramoplanin induced pertubation of pneumococcal peptidoglycan</gtr:description><gtr:id>A86AE7DA-436A-4DF0-A058-FBBEFFF6D037</gtr:id><gtr:impact>assisted in pureparation of cell wall intermediates</gtr:impact><gtr:partnerContribution>assisted the company in pure paration of cell wall intermediates</gtr:partnerContribution><gtr:piContribution>Advice</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Prolysis Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Prolysis</gtr:description><gtr:id>7C0C2BA4-8386-47CA-99AD-CCE8C1552426</gtr:id><gtr:impact>Prolysis have been involved in the development of a large transnational programme grant and lloyd Czaplewski still remains in close contact advising us from and industrial pharma perspective</gtr:impact><gtr:partnerContribution>Intellectual input and advice relating to direction in two translational grant applications</gtr:partnerContribution><gtr:piContribution>We have assisted in compound screen and assay development</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Warwick University iCAST</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DC36CCDA-3E2F-48D2-B148-29B248257917</gtr:id><gtr:impact>Communication to UK and global audience

Further media contacts</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Regional news papers</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>FCBE5402-B8F4-42D1-AC05-9F1293B8F5E5</gtr:id><gtr:impact>Contribution to regional news

Further contacts from regional and national media</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2006,2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ANTRUK Antibiotic Research UK</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>79E4A171-106C-47FF-BD2C-139DA9DE01F4</gtr:id><gtr:impact>Establishment of new charity and new fundraising campaign

regional and national media interest</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.antibioticresearch.org.uk</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Flemming video</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>626240C9-A156-43B0-8623-53E91F7E472D</gtr:id><gtr:impact>100000. Short film presentation linking our current MRC funded research to the groundbreaking work by alexander Flemming

to be released later this year as part of the MRC celebrations</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Getting to grips with antibiotic resistance</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>1C3FEA2B-008C-4840-A227-526CD924A679</gtr:id><gtr:impact>The School of Life Sciences at Warwick hosted members of the public and press for a presentational evening with talks, lab tours and demonstrations in an event entitled: &amp;quot;Getting to grips with antibiotic resistance&amp;quot; This event was held in antibiotic awareness week in November 2016 and hosted around 90 visitor</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:url>http://www2.warwick.ac.uk/fac/sci/lifesci/outreach/next/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>3200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC AMR theme 1 collaboration award</gtr:description><gtr:end>2020-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>DB66589E-4687-425E-896A-CCE0CDF2FD07</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Pathfinder Award</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>98263F2B-2472-4D9D-842F-D65795B4A7B2</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CIHR /MRC team grant</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>5E7EF0CF-3030-4E8C-B031-60FA7C31368A</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>464000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC LINK award</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/K017268/1</gtr:fundingRef><gtr:id>675E8963-661E-430D-87D8-D2E2AACA4814</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Accelerate CHNUK AMR discovery: Establishing joint China/UK training and research platforms enabling highthroughput fragment based inhibitor discovery</gtr:description><gtr:end>2019-05-02</gtr:end><gtr:fundingOrg>Newton Fund</gtr:fundingOrg><gtr:fundingRef>MR/P007503/1	</gtr:fundingRef><gtr:id>C6A3DFA1-D899-4D38-B59E-4F68EC1F7DA6</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2016-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>264000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BaCWAN2</gtr:description><gtr:end>2010-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>8D7D3102-CD1D-4186-9377-25B53063BCE4</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>flexible interchange partnership FLIP</gtr:description><gtr:end>2016-02-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>FE3B606E-0966-4C03-BC51-59223668FD96</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2014-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UK CAN BaCWAN</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>0FD09CDE-533D-47DA-BE0E-6748BC9C0CD6</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>589000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>62DF7C25-0EB0-403A-AEA0-706CDADC3DA0</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Optimisation of peptidoglycan pathway intermediates synthesis and purification</gtr:description><gtr:id>8FAA515F-0EA3-4C75-83B3-CDA96809CD9C</gtr:id><gtr:impact>Development of a synthesis facility to provide thes eintemediates to the global research community and the fundamental platform for several UK and international peptidoglycan networks</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Synthesis of peptidoglycan intermediates</gtr:title><gtr:yearProtectionGranted>2006</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>All Party Parliamentary Group on Antimicrobial Resistance</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>27A744A2-14C6-436E-8FCE-BF1A2C695F43</gtr:id><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Canada/UK AMR Workshop</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>7A24122D-1DE4-429D-83C9-6E5381B679D3</gtr:id><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MRC strategic review on antimicrobial resistance</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A509E679-5353-44AB-A0F7-F5D9BE4DAE61</gtr:id><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lessons to be learnt from pharma A summary of an interactive one-day symposium about discovery and development of new antibacterial drugs 1 Lessons to be learnt from pharma about discovery and development of new antibacterial drugs</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>84BF7B60-6AFB-4BFE-BB1E-9936211468B9</gtr:id><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Capacity to synthesise peptidoglycan intermediates at high purity and semi-commercial quantities</gtr:description><gtr:id>8A9522AB-70A4-464E-9CFE-C3DEC3BB173C</gtr:id><gtr:impact>Access of reagents to the wider community - supplied over 40 research groups worldwide</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>peptidoglycan pathway intermediates</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>First in class continuous quantitative bifunctional PBP assay</gtr:description><gtr:id>5D0BB0AD-AF6C-419C-93DC-7CC1D1C4AB07</gtr:id><gtr:impact>Use in HTS assay with Astra Zeneca</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>New assays for penicillin binding proteins</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Antimicrobial Discovery Solutions Ltd</gtr:companyName><gtr:description>Reagents, assay development and services</gtr:description><gtr:id>773E791D-4697-4AD0-A9AE-34865BB953DA</gtr:id><gtr:impact>N/A</gtr:impact><gtr:yearCompanyFormed>2015</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5300ACE8-425A-4AFD-BFC9-0441BA6A6363"><gtr:id>5300ACE8-425A-4AFD-BFC9-0441BA6A6363</gtr:id><gtr:title>Adenosine phosphonate inhibitors of lipid II: alanyl tRNA ligase MurM from Streptococcus pneumoniae.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6fc69d5be4c1fa2234e04140b7de0313"><gtr:id>6fc69d5be4c1fa2234e04140b7de0313</gtr:id><gtr:otherNames>Cressina E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/95C46E0B-BC69-43EA-9094-A95CB1E4BD30"><gtr:id>95C46E0B-BC69-43EA-9094-A95CB1E4BD30</gtr:id><gtr:title>Kinetic characterization of lipid II-Ala:alanyl-tRNA ligase (MurN) from Streptococcus pneumoniae using semisynthetic aminoacyl-lipid II substrates.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5cff8d9647660a115bdcd0780da91b57"><gtr:id>5cff8d9647660a115bdcd0780da91b57</gtr:id><gtr:otherNames>De Pascale G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AA0147EF-4B3D-4700-A334-8699A2D3DE20"><gtr:id>AA0147EF-4B3D-4700-A334-8699A2D3DE20</gtr:id><gtr:title>Inhibition of tRNA-dependent ligase MurM from Streptococcus pneumoniae by phosphonate and sulfonamide inhibitors.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6fc69d5be4c1fa2234e04140b7de0313"><gtr:id>6fc69d5be4c1fa2234e04140b7de0313</gtr:id><gtr:otherNames>Cressina E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0968-0896</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/80E4ADB6-231D-462D-BEBB-FBCFA807A4FA"><gtr:id>80E4ADB6-231D-462D-BEBB-FBCFA807A4FA</gtr:id><gtr:title>Crystal structures of penicillin-binding protein 3 (PBP3) from methicillin-resistant Staphylococcus aureus in the apo and cefotaxime-bound forms.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8f180a15663e642d6e2c71c1a59a300b"><gtr:id>8f180a15663e642d6e2c71c1a59a300b</gtr:id><gtr:otherNames>Yoshida H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/773F246A-1A0D-48C7-8DB1-69DA44D7BF88"><gtr:id>773F246A-1A0D-48C7-8DB1-69DA44D7BF88</gtr:id><gtr:title>Adenosine tetraphosphoadenosine drives a continuous ATP-release assay for aminoacyl-tRNA synthetases and other adenylate-forming enzymes.</gtr:title><gtr:parentPublicationTitle>ACS chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7d9a44e5e7a61959fd7e4276275fb157"><gtr:id>7d9a44e5e7a61959fd7e4276275fb157</gtr:id><gtr:otherNames>Lloyd AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1554-8929</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2CDDCF41-0B31-49AC-B8C7-E0E84AF5F549"><gtr:id>2CDDCF41-0B31-49AC-B8C7-E0E84AF5F549</gtr:id><gtr:title>Characterization of tRNA-dependent peptide bond formation by MurM in the synthesis of Streptococcus pneumoniae peptidoglycan.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7d9a44e5e7a61959fd7e4276275fb157"><gtr:id>7d9a44e5e7a61959fd7e4276275fb157</gtr:id><gtr:otherNames>Lloyd AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DDFD5DFA-FBC4-4F3D-8597-BF8788D8AC6E"><gtr:id>DDFD5DFA-FBC4-4F3D-8597-BF8788D8AC6E</gtr:id><gtr:title>Fluorescent reagents for in vitro studies of lipid-linked steps of bacterial peptidoglycan biosynthesis: derivatives of UDPMurNAc-pentapeptide containing d-cysteine at position 4 or 5.</gtr:title><gtr:parentPublicationTitle>Molecular bioSystems</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ee62c7d4e797a1b215c3e09aba0b983d"><gtr:id>ee62c7d4e797a1b215c3e09aba0b983d</gtr:id><gtr:otherNames>Schouten JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1742-2051</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/569A530B-DA35-44F7-884D-85405AC160B4"><gtr:id>569A530B-DA35-44F7-884D-85405AC160B4</gtr:id><gtr:title>Mutational analysis of the substrate specificity of Escherichia coli penicillin binding protein 4.</gtr:title><gtr:parentPublicationTitle>Biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/32918b04931fabb0631d6ae72adc8bf8"><gtr:id>32918b04931fabb0631d6ae72adc8bf8</gtr:id><gtr:otherNames>Clarke TB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-2960</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CD4144F7-47CB-4A52-9CA3-38CACFD7D2B1"><gtr:id>CD4144F7-47CB-4A52-9CA3-38CACFD7D2B1</gtr:id><gtr:title>Nod1 signaling overcomes resistance of S. pneumoniae to opsonophagocytic killing.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cff11cd2c359666d4f4782b083b20fb1"><gtr:id>cff11cd2c359666d4f4782b083b20fb1</gtr:id><gtr:otherNames>Lysenko ES</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400848</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>